- The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause
- Lexaria’s patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing
- The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026
In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control. According to the Centers for Disease Control and Prevention (“CDC”), in 2020, more than 670,000 deaths in the United States had high blood pressure as a primary or contributing cause (https://cnw.fm/oH9ZC). Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that its human clinical study HYPER-H21-4 may be the world’s first study to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM)-enabled CBD capsule formulation.
According to company CEO Chris Bunka, this is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit. Additionally, DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study (https://cnw.fm/9bluE).
“Indeed, of the handful of minor, non-serious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD,” Bunka added. “Consistent with Lexaria’s often-mentioned de-risking strategy, this exceptional safety profile should prove beneficial as we prepare for our planned upcoming Phase Ib Investigational New Drug clinical study to be registered with the U.S. Food and Drug Administration.”
The primary safety and efficacy objectives of the HYPER-H21-4 study were achieved, with a significant reduction in blood pressure achieved in 2.5 weeks and over the course of the five weeks of dosing. During the trial, zero serious adverse events were reported. No adverse changes were observed in liver enzymes, which is an important clinical safety biomarker of oral CBD therapy. The study notes that a significant blood pressure decrease was achieved using relatively low doses of DehydraTECH-CBD, a key indicator of the well-established drug delivery efficiencies of the company’s technology – with superior power evidenced through its unique formulation to reduce blood pressure over other oral CBD formulation (https://cnw.fm/NVoDQ).
The positive findings emphasize Lexaria’s unique position to address the unmet needs of the growing antihypertension drug market. The industry was responsible for $22,557 million in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in $28,797 million by 2026 (https://cnw.fm/jISXH).
Lexaria’s DehydraTECH technology was designed for formulating and delivering lipophilic drugs and active ingredients. It increases effectiveness and improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream. The benefits of Lexaria’s DehydraTECH technology include the following:
- Speeds up the delivery so that effects are felt in minutes
- Increased bioavailability
- Increased brain absorption
- Improves drug potency
- Reduces drug administration costs so that lower doses are necessary
- Masks unwanted taste, eliminating and reducing the need for sweeteners
Since 2016, Lexaria has demonstrated, through its DehydraTECH technology, the ability to increase bio-absorption by up to five to ten times. It has reduced the onset time from one to two hours to just minutes. It will be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, nicotine and more.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.hempwire.com
Do you have a questions or are you interested in working with HW? Ask our Editor
HempWire is part of the InvestorBrandNetwork.